Alterity Therapeutics Limited
NASDAQ: ATHE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David A. Stamler
- Employees
- 10
- Headquarters
- Melbourne, Australia
- IPO year
- 2003
- Market cap
- $45.9M
- Website
- https://alteritytherapeutics.com
Loading ATHE…
Loading profile data…Frequently asked questions about ATHE
What does Alterity Therapeutics Limited (ATHE) do?
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. Th...
Where does ATHE trade?
Alterity Therapeutics Limited (ATHE) trades on the NASDAQ Capital Market.
What sector is ATHE in?
Alterity Therapeutics Limited (ATHE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Alterity Therapeutics Limited?
David A. Stamler is the chief executive officer of Alterity Therapeutics Limited (ATHE).
Where is Alterity Therapeutics Limited headquartered?
Alterity Therapeutics Limited is headquartered in Australia.
Does ATHE pay a dividend?
Alterity Therapeutics Limited (ATHE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ATHE go public?
Alterity Therapeutics Limited (ATHE) completed its initial public offering in 2003.
Is ATHE an ADR?
Yes — ATHE is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Alterity Therapeutics Limited reporting and dividends follow the underlying issuer.